OtherAccelerated Communication
A NEW CLASS OF CYP2C9 INHIBITORS: PROBING 2C9 SPECIFICITY WITH HIGH-AFFINITY BENZBROMARONE DERIVATIVES
Charles W. Locuson II, Jan L. Wahlstrom, Denise A. Rock, Dan A. Rock and Jeffrey P. Jones
Drug Metabolism and Disposition July 2003, 31 (7) 967-971; DOI: https://doi.org/10.1124/dmd.31.7.967